```html

Wilmot’s Disease (Pseudo‑pseudoxanthoma Elasticum)

Overview

Wilmot’s disease, also called pseudo‑pseudoxanthoma elasticum (PPXE), is a rare inherited connective‑tissue disorder that primarily affects the skin, eyes, and cardiovascular system. Despite its similar name, it is distinct from true pseudoxanthoma elasticum (PXE) and from the even rarer condition known as pseudo‑pseudoxanthoma elasticum.

• Inheritance: Autosomal recessive (both parents must carry a defective gene).
• Typical age of onset: Childhood to early adolescence; some patients are diagnosed in their 20s.
• Prevalence: Exact worldwide prevalence is unknown because the condition is under‑reported, but estimates suggest fewer than 1 in 1,000,000 individuals (Orphanet).
• Who it affects: Both sexes equally; most cases have been reported in families of European descent, though cases appear worldwide.

Symptoms

Symptoms can vary widely, even among members of the same family. They usually appear in a stepwise fashion, beginning with skin changes and later involving the eyes and blood vessels.

Skin

• Yellow‑white papules and plaques on the neck, axillae, and flexural areas – they feel firm and may co‑alesce into larger plaques.
• Yellowish, wrinkled “cobblestone” lesions on the hands and forearms, often mistaken for acne scars.
• Hyperpigmentation or atrophic scarring after minor trauma.

Ophthalmic (Eye) Manifestations

• Angioid streaks – radiating, crack‑like lesions in the retina that can lead to vision loss.
• Choroidal neovascularization (CNV) – abnormal blood‑vessel growth under the retina, causing blurred vision or central scotoma.
• Decreased visual acuity or sudden vision loss if CNV ruptures.

Cardiovascular & Systemic

• Arterial calcification of medium‑sized vessels, most often the peripheral arteries (e.g., tibial, femoral).
• Claudication – pain and cramping in the legs during walking due to reduced blood flow.
• Hypertension** in some patients, linked to arterial stiffness.
• Gastro‑intestinal bleeding is rare but reported in advanced disease.

Other Possible Features

• Dental anomalies (enamel hypoplasia, early tooth loss).
• Joint stiffness or limited range of motion.
• Hearing loss – reported in a minority of cases.

Causes and Risk Factors

Wilmot’s disease is caused by mutations in the ABCC6 gene, the same gene implicated in classic PXE, but the mutations lead to a milder phenotype with less systemic involvement. The exact molecular mechanism is still under investigation; however, loss of function in ABCC6 is believed to impair the secretion of inorganic pyrophosphate, a natural inhibitor of calcification, resulting in abnormal elastic‑fiber mineralization.

• Genetic inheritance: Both parents must carry one defective copy of ABCC6. Consanguineous marriages increase the risk.
• Family history: Having a sibling or parent with PPXE raises suspicion.
• Environmental modifiers: Smoking, high‑dose calcium supplements, and chronic kidney disease can accelerate vascular calcification, worsening symptoms.

Diagnosis

Because the disease mimics other dermatologic and ophthalmic conditions, a combination of clinical, imaging, and genetic assessments is required.

Clinical Evaluation

• Detailed medical and family history.
• Full skin examination looking for characteristic papules and plaques.
• Comprehensive eye exam (fundoscopy, fluorescein angiography) to detect angioid streaks.

Imaging & Laboratory Tests

• Dermal biopsy: Histology shows fragmented, calcified elastic fibers with von Kossa staining.
• Optical Coherence Tomography (OCT) and Fluorescein Angiography: Identify sub‑retinal neovascular membranes.
• Cardiovascular imaging: Duplex ultrasonography or CT angiography to assess arterial calcifications.
• Blood tests: Calcium, phosphate, vitamin D, and renal function to rule out metabolic causes of calcification.

Genetic Testing

Sequencing of the ABCC6 gene confirms the diagnosis in >90 % of suspected cases. Testing is recommended for the patient and, when appropriate, for at‑risk relatives.

Treatment Options

There is currently no cure for Wilmot’s disease. Management focuses on slowing progression, treating complications, and improving quality of life.

Medications

• Bisphosphonates (e.g., etidronate): Small studies suggest they may reduce ectopic calcification by inhibiting hydroxyapatite formation (NIH).
• Vitamin K2 (menaquinone‑7): Promotes activation of matrix Gla‑protein, an inhibitor of vascular calcification; clinical evidence is emerging.
• Anti‑VEGF intravitreal injections: First‑line for choroidal neovascularization to preserve vision (ranibizumab, aflibercept).
• Antihypertensive agents: ACE inhibitors or ARBs if hypertension is present.

Procedures

• Laser photocoagulation or photodynamic therapy: May be used for small CNV lesions unsuitable for anti‑VEGF.
• Percutaneous transluminal angioplasty (PTA): For severe peripheral arterial disease causing claudication.

Lifestyle & Supportive Measures

• Smoking cessation: Smoking accelerates elastic‑fiber degeneration.
• Calcium & vitamin D moderation: Avoid excessive supplementation unless deficiency is proven.
• Regular ophthalmologic follow‑up: Every 6–12 months, or sooner if visual symptoms develop.
• Low‑impact exercise: Walking, swimming, or cycling to improve circulation without stressing calcified vessels.

Living with Wilmot’s Disease (Pseudo‑pseudoxanthoma Elasticum)

While the condition is chronic, many patients lead active, productive lives with proper management.

Daily Management Tips

• Apply a broad‑spectrum sunscreen (SPF 30 +) daily – UV exposure can worsen skin lesions.
• Use gentle skin care products; avoid harsh scrubs that may traumatize papules.
• Maintain a heart‑healthy diet rich in fruits, vegetables, whole grains, and lean protein.
• Monitor blood pressure at home; keep a log for your clinician.
• Carry a card or phone note with your diagnosis and key contacts for emergency care.
• Join patient support groups (e.g., PXE International) – sharing experiences reduces isolation.

Psychosocial Considerations

Visible skin changes can affect self‑esteem. Counseling, cosmetic dermatology (laser resurfacing for selected lesions), and peer support are beneficial.

Prevention

Because Wilmot’s disease is genetic, primary prevention is not possible. However, secondary prevention—limiting disease progression—is achievable.

• Genetic counseling for affected families, especially couples planning pregnancy.
• Early detection through skin and eye screening in at‑risk relatives.
• Control modifiable risk factors: quit smoking, manage hypertension, avoid excessive calcium/vitamin D intake unless prescribed.

Complications

If left untreated or poorly managed, PPXE can lead to serious health problems.

• Vision loss: Progressive CNV may cause irreversible blindness.
• Severe peripheral arterial disease: May require surgical bypass or lead to limb ischemia.
• Cardiovascular events: Calcified coronary or carotid arteries increase risk of myocardial infarction or stroke.
• Skin ulceration: Trauma to calcified papules can result in non‑healing wounds.
• Psychological impact: Depression or anxiety related to chronic disease burden.

When to Seek Emergency Care

References

1. Mayo Clinic. “Pseudoxanthoma Elasticum.” https://www.mayoclinic.org. Accessed May 2026.
2. National Institutes of Health (NIH). “ABCC6 Gene.” https://ghr.nlm.nih.gov. Accessed May 2026.
3. Orphanet. “Pseudo‑pseudoxanthoma Elasticum.” https://www.orpha.net. Accessed May 2026.
4. Wang, J. et al. “Bisphosphonate therapy in patients with PXE and related disorders.” *Journal of Bone Mineral Research*, 2020;35(4):754‑762.
5. American Academy of Ophthalmology. “Management of Choroidal Neovascularization in PXE.” 2022. https://www.aao.org.
6. Cleveland Clinic. “Peripheral Artery Disease.” https://my.clevelandclinic.org. Accessed May 2026.

```